Literature DB >> 8793462

Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis.

J B Cailes1, C O'Connor, P Pantelidis, A M Southcott, M X Fitzgerald, C M Black, R M du Bois.   

Abstract

Fibrosing alveolitis complicating systemic sclerosis (FASSc) carries a better prognosis than lone cryptogenic fibrosing alveolitis (CFA). We wanted to determine whether this improved prognosis is associated with differential neutrophil migration and activation in the lower respiratory tract. We therefore compared bronchoalveolar lavage (BAL) neutrophil numbers and levels of neutrophil-derived enzymes in FASSc, CFA and normal individuals. Bronchoalveolar lavage was performed on 45 subjects (FASSc n = 20; CFA n = 15; normals n = 10); cell counts and levels of neutrophil-derived enzymes, myeloperoxidase, elastase (total elastase and elastase/alpha 1 antitrypsin complexes), collagenase and lactoferrin were measured. Lung function testing was performed in subjects with fibrosing alveolitis. Significant differences in the levels of collagenase, myeloperoxidase and elastase/ alpha 1-antitrypsin complexes were present in the BAL fluid from the three groups. Patients with CFA had significantly higher neutrophil percentages and levels of collagenase and myeloperoxidase than those with FASSc. Disease extent, as judged by lung volumes and gas transfer, was comparable in the CFA and FASSc groups. Forced vital capacity (% predicted) was significantly lower in patients with evidence of increased neutrophil enzyme release than those without. We conclude that: 1) increased neutrophil migration to the lung is accompanied by release both of primary and secondary granule enzymes in cryptogenic fibrosing alveolitis; and 2) the lower amounts of neutrophil products in fibrosing alveolitis complicating systemic sclerosis may account for the improved prognosis, even when disease is as extensive as in cryptogenic fibrosing alveolitis.

Entities:  

Mesh:

Year:  1996        PMID: 8793462     DOI: 10.1183/09031936.96.09050992

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome.

Authors:  A Schnabel; E Csernok; J Braun; W L Gross
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 3.  Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.

Authors:  Kristin B Highland; Richard M Silver
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

5.  Idiopathic Interstitial Pneumonia as a Possible Cause of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Report.

Authors:  Hiroshi Oiwa; Katsuhiro Ooi; Tetsu Oyama; Eiji Sugyama
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

6.  Comparison of clinicoradiologic manifestation of nonspecific interstitial pneumonia and usual interstitial pneumonia/idiopathic pulmonary fibrosis: a report from NRITLD.

Authors:  Saeid Fallah Tafti; Bahareh Mokri; Foroozan Mohammadi; Mehrdad Bakhshayesh-Karam; Habib Emami; Mohammad Reza Masjedi
Journal:  Ann Thorac Med       Date:  2008-10       Impact factor: 2.219

7.  Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.

Authors:  Sergey Udalov; Rio Dumitrascu; Soni S Pullamsetti; Hamza M Al-tamari; Norbert Weissmann; Hossein A Ghofrani; Andreas Guenther; Robert Voswinckel; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  BMC Pulm Med       Date:  2010-05-05       Impact factor: 3.317

8.  Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo.

Authors:  Subbiah Rajasekaran; Michelle Vaz; Sekhar P Reddy
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.